Table 1.
Degree to financial burden by patients’ characteristics (n = 1549).
| Patients’ Characteristics | n (%) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Overall | Subjective Financial Burden | Objective Financial Burden | |||||||
| Low | Moderate | High | p-Value | Low | Moderate | High | p-Value | ||
| Sex | |||||||||
| Male | 808 (52.2) | 297 (36.8) | 238 (29.5) | 273 (33.8) | 0.078 | 353 (43.7) | 129 (16.0) | 326 (40.3) | 0.254 |
| Female | 741 (47.8) | 314 (42.4) | 199 (26.9) | 228 (30.8) | 304 (41.0) | 141 (19.0) | 296 (39.9) | ||
| Age | |||||||||
| ≤30 | 207 (13.4) | 71 (34.3) | 53 (25.6) | 83 (40.1) | 0.267 | 86 (41.5) | 27 (13.0) | 94 (45.4) | 0.218 |
| 31–40 | 503 (32.5) | 201 (40.0) | 138 (27.4) | 164 (32.6) | 217 (43.1) | 87 (17.3) | 199 (39.6) | ||
| 41–50 | 430 (27.8) | 171 (39.8) | 121 (28.1) | 138 (32.1) | 184 (42.8) | 79 (18.4) | 167 (38.8) | ||
| 51–60 | 265 (17.1) | 110 (41.5) | 80 (30.2) | 75 (28.3) | 102 (38.5) | 57 (21.5) | 106 (40.0) | ||
| ≥61 | 141 (9.1) | 58 (41.1) | 45 (31.9) | 38 (27.0) | 68 (48.2) | 18 (12.8) | 55 (39.0) | ||
| Educational attainment | |||||||||
| No/Primary | 207 (13.4) | 49 (23.7) | 48 (23.2) | 110 (53.1) | <0.001 | 59 (28.5) | 29 (14.0) | 119 (57.5) | <0.001 |
| Secondary/Post-secondary | 699 (45.1) | 223 (31.9) | 212 (30.3) | 264 (37.8) | 272 (38.9) | 125 (17.9) | 302 (43.2) | ||
| Tertiary or above | 643 (41.5) | 339 (52.7) | 177 (27.5) | 127 (19.8) | 326 (50.7) | 116 (18.0) | 201 (31.3) | ||
| Health Insurance ^ | |||||||||
| UEBMI/URBMI | 1165 (75.2) | 128 (33.3) | 94 (24.5) | 162 (42.2) | <0.001 | 511 (43.9) | 211 (18.1) | 443 (38.0) | <0.001 |
| NCMS | 203 (13.1) | 36 (17.7) | 52 (25.6) | 115 (56.7) | 64 (31.5) | 28 (13.8) | 111 (54.7) | ||
| CIS | 94 (6.1) | 64 (68.1) | 21 (22.3) | 9 (9.6) | 54 (57.4) | 16 (17.0) | 24 (25.5) | ||
| No insurance | 12 (0.8) | 3 (25.0) | 3 (25.0) | 6 (50.0) | 2 (16.7) | 0 | 10 (83.3) | ||
| Family register | |||||||||
| Urban residents | 1170 (75.5) | 513 (43.8) | 332 (28.4) | 325 (27.8) | <0.001 | 529 (45.2) | 209 (17.9) | 432 (36.9) | <0.001 |
| Rural residents | 372 (24.5) | 92 (24.7) | 105 (28.2) | 175 (47.0) | 124 (33.3) | 60 (16.1) | 188 (50.5) | ||
| Duration of disease (years) | |||||||||
| 1–3 | 785 (58.5) | 310 (39.5) | 223 (28.4) | 252 (32.1) | 0.552 | 203 (25.9) | 145 (18.5) | 437 (55.7) | <0.001 |
| 4–6 | 395 (29.5) | 174 (44.1) | 93 (23.5) | 128 (32.4) | 215 (54.4) | 76 (19.2) | 104 (26.3) | ||
| 7–10 | 120 (9.0) | 47 (39.2) | 34 (28.3) | 39 (32.5) | 70 (58.3) | 19 (15.8) | 31 (25.8) | ||
| ≥10 | 40 (3.0) | 17 (42.5) | 13 (32.5) | 10 (25.0) | 24 (60.0) | 5 (12.5) | 11 (27.5) | ||
| Family income (USD/year) | |||||||||
| ≤20000 | 496 (51.3) | 199 (40.1) | 151 (30.4) | 146 (29.4) | <0.001 | 198 (39.9) | 87 (17.5) | 211 (42.5) | <0.001 |
| 20001–30000 | 268 (27.7) | 152 (56.7) | 77 (28.7) | 39 (14.6) | 146 (54.5) | 54 (20.1) | 68 (25.4) | ||
| 30001–50000 | 115 (11.9) | 77 (67.0) | 23 (20.0) | 15 (13.0) | 72 (62.6) | 28 (24.3) | 15 (13.0) | ||
| ≥50001 | 88 (9.1) | 72 (81.8) | 11 (12.5) | 5 (5.7) | 75 (85.2) | 12 (13.6) | 1 (1.1) | ||
| Chemotherapy | |||||||||
| Yes | 1292 (90.2) | 487 (37.7) | 356 (27.6) | 449 (34.8) | 0.009 | 489 (37.8) | 233 (18.0) | 570 (44.1) | <0.001 |
| No | 141 (9.8) | 65 (46.1) | 45 (31.9) | 31 (22.0) | 78 (55.3) | 22 (15.6) | 41 (29.1) | ||
| Immunotherapy | |||||||||
| Yes | 609 (42.5) | 241 (39.6) | 176 (28.9) | 192 (31.5) | 0.396 | 244 (40.1) | 105 (17.2) | 260 (42.7) | 0.882 |
| No | 824 (57.5) | 311 (37.7) | 225 (27.3) | 288 (35.0) | 323 (39.2) | 150 (18.2) | 351 (42.6) | ||
| Radiation therapy | |||||||||
| Yes | 308 (21.5) | 140 (45.5) | 79 (25.6) | 89 (28.9) | 0.017 | 109 (35.4) | 61 (19.8) | 138 (44.8) | 0.217 |
| No | 1125 (78.5) | 412 (36.6) | 322 (28.6) | 391 (34.8) | 458 (40.7) | 194 (17.2) | 473 (42.0) | ||
| Surgery | |||||||||
| Yes | 221 (15.4) | 80 (36.2) | 59 (26.7) | 82 (37.1) | 0.46 | 94 (42.5) | 32 (14.5) | 95 (43.0) | 0.332 |
| No | 1212 (84.6) | 472 (38.9) | 342 (28.2) | 398 (32.8) | 473 (39.0) | 223 (18.4) | 516 (42.6) | ||
| Treatment status | |||||||||
| Never be treated (no need for treatment) | 116 (7.5) | 59 (50.9) | 36 (31.0) | 21 (18.1) | <0.001 | 90 (77.6) | 15 (12.9) | 11 (9.5) | <0.001 |
| Currently not undertreatment (improved due to last treatment) | 122 (7.9) | 59 (48.4) | 26 (21.3) | 37 (30.3) | 70 (57.4) | 20 (16.4) | 32 (26.2) | ||
| Under treatment | 612 (39.5) | 180 (29.4) | 197 (32.2) | 235 (38.4) | 240 (39.2) | 117 (19.1) | 255 (41.7) | ||
| Treatment just completed | 699 (45.1) | 313 (44.8) | 178 (25.5) | 208 (29.8) | 257 (36.8) | 118 (16.9) | 324 (46.4) | ||
| Sub-types | |||||||||
| CLL | 158 (10.2) | 66 (41.8) | 50 (31.6) | 42 (26.6) | <0.001 | 98 (62.0) | 27 (17.7) | 33 (20.9) | <0.001 |
| FL | 359 (23.2) | 149 (41.5) | 106 (29.5) | 104 (29.0) | 159 (44.3) | 76 (21.2) | 124 (34.5) | ||
| LPL | 31 (2.0) | 12 (38.7) | 9 (29.0) | 10 (32.3) | 17 (54.8) | 3 (9.7) | 11 (35.5) | ||
| MALT | 86 (5.6) | 42 (48.8) | 22 (25.6) | 22 (25.6) | 41 (47.7) | 16 (18.6) | 29 (33.7) | ||
| MCL | 76 (4.9) | 10 (13.2) | 22 (28.9) | 44 (57.9) | 23 (30.3) | 17 (22.4) | 36 (47.4) | ||
| DLBCL | 583 (37.6) | 249 (42.7) | 159 (27.3) | 175 (30.0) | 238 (40.8) | 91 (15.6) | 254 (43.6) | ||
| BL | 27 (1.7) | 6 (22.2) | 8 (29.6) | 13 (48.1) | 11 (40.7) | 2 (7.4) | 14 (51.9) | ||
| T-LBL | 35 (2.3) | 7 (20.0) | 6 (17.1) | 22 (62.9) | 9 (25.7) | 4 (11.4) | 22 (62.9) | ||
| ENKL | 114 (7.4) | 43 (37.7) | 32 (28.1) | 39 (34.2) | 38 (33.3) | 23 (20.2) | 53 (46.5) | ||
| PTCL | 34 (2.2) | 11 (32.4) | 10 (29.4) | 13 (38.2) | 3 (8.8) | 6 (17.6) | 25 (73.5) | ||
| PC-ALCL | 46 (3.0) | 16 (34.8) | 13 (28.3) | 17 (37.0) | 20 (43.5) | 5 (17.4) | 21 (40.2) | ||
UEBMI, urban employee basic medical insurance; URBMI, urban resident basic medical insurance; NCMS, New rural cooperative medical scheme; CIS, commercial insurance scheme. ^ 75 respondents did not report. CLL, chronic lymphocytic leukemia; FL, Follicular lymphoma; LPL, Lymphoplasmacytic lymphoma; MALT, Mucosa associated lymphoid tissue type; MCL, Mantle cell lymphoma; DLBCL, Diffuse large B cell lymphoma; BL, Burkitt lymphoma; T-LBL, T-cell lymphoblastic lymphoma; ENKL, Extranodal natural killer (NK)/T-cell lymphoma; PTCL, peripheral T cell lymphoma; PC-ALCL, primary cutaneous anaplastic large cell lymphoma.